<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benefit of warfarin in chronic atrial fibrillation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benefit of warfarin in chronic atrial fibrillation</h1>
<div class="graphic"><div class="figure"><div class="ttl">Benefit of warfarin in chronic atrial fibrillation</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Efficacy of anticoagulation with warfarin to prevent ischemic stroke and other thromboemboli in 4 major studies. An intention to treat approach was used, and transient ischemic attack and hemorrhage were excluded. The numbers at the top represent the risk reduction with warfarin therapy, which ranged from 45 to 82%.</div><div class="graphic_footnotes">SPAF: Stroke Prevention in Atrial Fibrillation; AFASAK: Copenhagen AFASAK Study; BAATAF: Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA: Canadian Atrial Fibrillation Anticoagulation Study.<br/>* The data in the warfarin group in the SPAF assumes that half of the events were attributable to warfarin toxicity.</div><div class="graphic_reference">Data from: Connolly SJ, Laupacis AN, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18:349.</div><div id="graphicVersion">Graphic 79839 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
